IP Library › Granted Patent US 12,606,548
Granted Patent B2
US 12,606,548 · App. 18/204,726 · Granted Apr 21, 2026

Fungicidal oxadiazoles

Inventors: Robert James Pasteris (Newark, DE); Srinivas Chittaboina (Bibipet, IN); Travis Chandler McMahon (Middletown, DE); Balreddy Kamireddy (Hockessin, DE); Ravisekhara Pochimireddy Reddy (Secunderabad, IN)
Assignee: FMC CORPORATION
C07D413/10A01N43/82A01N43/84C07D271/06C07D413/04C07D413/12C07D413/14C07D417/10C07D471/04C07D487/04C07D498/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,606,548
App. No.
18/204,726
Granted
Apr 21, 2026
Kind
B2
Abstract

Disclosed are compounds of Formula 1, including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein R 1 , L and J are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.

Claims (21)

1 . A compound selected from Formula 3 and salts thereof,

wherein

R 1 is

wherein U-2 is connected at its 2-position to L;

x is 1;

L is CH 2 ;

J is

wherein the bond projecting to the left is bonded to L, and the bond projecting to the right is bonded to the C═N group in Formula 3;

each R 5a is H;

R 2 is-C(═O) NR 3a R 3b ;

each R 3a is H; and

each R 3b is C 1 -C 3 alkyl, C 1 -C 3 haloalkyl or C 2 -C 4 alkoxyalkyl.

2 . A compound of claim 1 that is:

wherein:

R 2 is ClCH 2 CH 2 NHC(═O); or

R 2 is F 2 CHCH 2 NHC(═O); or

R 2 is MeOCH 2 CH 2 NHC(═O); or

R 2 is CF 3 CH 2 CH 2 NHC(═O); or

R 2 is FCH 2 CH 2 NHC(═O); or

R 2 is CF 3 CH 2 NHC(═O).

3 . A compound of claim 2 that is:

Assignments (1)
PATENT SECURITY AGREEMENT Recorded Apr 17, 2026
From: FMC CORPORATION
To: CITIBANK, N.A.
Reel/Frame 075403/0891 →
Continuity (2)
Division 16603449 · Oct 7, 2019
Related Publication 20240166638A1 · May 23, 2024
References Cited (52)
US 20050203188A1 · Ammermann et al. · 2005 [cited by applicant]
EP 0276432A2 · 1987 [cited by applicant]
EP 0477141A1 · 1992 [cited by applicant]
EP 677218A1 · 1994 [cited by applicant]
EP 2065377A1 · 2009 [cited by applicant]
EP 2246338A1 · 2010 [cited by applicant]
EP 2729454B1 · 2014 [cited by applicant]
JP 04247075A · 1992 [cited by applicant]
JP 0687857A · 1994 [cited by applicant]
JP 09263063A · 1997 [cited by applicant]
JP 9304931A · 1997 [cited by applicant]
JP 11171877A · 1999 [cited by applicant]
JP 2019089711A · 2019 [cited by applicant]
KR 1020100110834A · 2010 [cited by applicant]
WO 9216527A · 1992 [cited by applicant]
WO 199405153A1 · 1994 [cited by applicant]
WO 200015637A1 · 2000 [cited by applicant]
WO 2008074820A1 · 2008 [cited by applicant]
WO 2013066839A2 · 2013 [cited by applicant]
WO 20130066838A1 · 2013 [cited by applicant]
WO 20130066839A2 · 2013 [cited by applicant]
WO 20130080120A1 · 2013 [cited by applicant]
WO 20140154612A1 · 2014 [cited by applicant]
WO 20150185485A1 · 2015 [cited by applicant]
WO 20170055473A1 · 2017 [cited by applicant]
WO 20170076740A1 · 2017 [cited by applicant]
WO 20170085098A1 · 2017 [cited by applicant]
WO 20170085100A1 · 2017 [cited by applicant]
WO 20170093348A1 · 2017 [cited by applicant]
WO 20170118689A1 · 2017 [cited by applicant]
WO 20170178549A1 · 2017 [cited by applicant]
WO 20170213252A1 · 2017 [cited by applicant]
WO 20170220485A1 · 2017 [cited by applicant]
WO 20180080859A1 · 2018 [cited by applicant]
WO 20180118781A1 · 2018 [cited by applicant]
WO 2018158365A1 · 2018 [cited by applicant]
RN 2253527-54-5; Dec. 17, 2018 (Year: 2016). [cited by examiner]
Lima et al., “Bioisosterism: A Useful Strategy for Molecular Modification and Drug Design”, Current Medicinal Chemistry, 2005, vol. 12, No. 1, p. 23-49. [cited by applicant]
Li et al., “Rhodium-catalyzed synthesis of unsymmetrical di(aryl/heteroaryl)methanes using aryl/heteroarylmethyl ketones via CO—C bond cleavage”, Chem. Commun., 2014, 50, 4328. [cited by applicant]
Molander et al., “Suzuki-Miyaura Cross-Coupling of Potassium Trifluoro(N-methylheteroaryl)borates with Aryl and Heteroaryl Halides”, J. Org. Chem, 2013, 78, 6648-6656. [cited by applicant]
CAS Registry No. 198641-33-7. [cited by applicant]
CAS Registry No. 197176-48-0. [cited by applicant]
CAS Registry No. 1537736-56-3. [cited by applicant]
CAS Registry No. 1518327-81-5. [cited by applicant]
CAS Registry No. 956780-58-8. [cited by applicant]
CAS Registry No. 1015532-78-1. [cited by applicant]
CAS Registry No. 1890322-79-8. [cited by applicant]
CAS Registry No. 1178398-64-5. [cited by applicant]
CAS Registry No. 1042644-90-5. [cited by applicant]
Xiao et al., “Dimethyl 1-(4-cyanobenzyl)-1H-pyrazole-3,5-dicarboxylate”, Acta Crystallographica E65, 2009, o1175. [cited by applicant]
Synthesis and Antitubercular Activity of 5-benzyl-3-phenyl dihydroisoxazoles, S.S. Bisht et.al., International Journal of Drug Design and Discovery, 2010, 1(1), p. 11-18. [cited by applicant]
Bioisosterism: a rational approach in drug design, Patani, G. A., & LaVoie, E. J., Chemical reviews, 96(8), 3147-3176, 1996. [cited by applicant]